Semax: gene activity, protein and movement
A nerve-growth protein, an RNA measurement and an animal walking test can all produce a positive result. They tell different stories about Semax.
BDNF: protein measurements and RNA
The 2006 Semax experiment in rats found increased BDNF protein in the basal forebrain three hours after administration, with no corresponding increase in the cerebellum. BDNF is a protein involved in nerve growth and maintenance. The paper also describes specific, reversible, calcium-dependent binding in vitro in rat basal-forebrain membranes and rat-derived astrocyte cultures.
A different rat experiment in 2007 examined messenger RNA, the copies of genetic instructions that cells use to make proteins. NGF and BDNF messages rose in the hippocampus; BDNF messages also rose in the brainstem and cerebellum, while NGF messages fell in frontal cortex.
I once let the word “expression” blur those experiments together. The distinction is consequential: one measured finished protein, the other the messages for making it. Even the cerebellum has a different-looking result when the measured object changes. Different experiments also bring different conditions; this is no direct contradiction between the papers.
The molecular activity is interesting on its own. Better recall in healthy people would require a study that measured recall in healthy people.
After brain or spinal injury
The animal recovery studies ask a more tangible question. In a rat model of focal brain ischaemia, Semax reduced the volume of damaged cortex and improved retention of a learned passive-avoidance response. Ischaemia means a shortage of blood supply. The task concerns remembering an avoidance response after injury.
The 2025 spinal-cord experiment in female mice measured locomotor recovery through walking, inclined-plane and footprint tests. Recovery improved, and an inflammatory form of cell death was reduced. The proposed mechanism involved the mu-opioid-receptor gene Oprm1, USP18 and the FTO protein.
The mouse footprints make recovery tangible to me. A movement outcome sits beside the molecular explanation, so the experiment has more than a biochemical change to discuss. Its context remains a surgically injured mouse, with human recovery still an open question.
Immune and vascular gene activity
In a 2014 experiment after an artery was blocked in rat brains, more than half of the affected genes concerned immune processes, and vascular-system genes also changed. That broadens the possible explanation of protection beyond a single nerve-growth factor.
I hesitate to hand BDNF the whole credit when this experiment describes such a substantial immune component. The study measured gene activity in injured tissue. The relative contributions of those changes to recovery need further work.
Semax structure and assay material
Semax combines part of ACTH with added amino acids that slow enzymatic breakdown. It lacks the cortisol-releasing action of the full hormone. Its chemical ancestry therefore describes a starting structure, rather than importing the entire hormone's action.
A rat study tracking Semax after intranasal administration detected material in brain tissue within about two minutes, with some already broken down. A cell-free experiment using human serum found inhibition of enzymes that degrade enkephalins, substances involved in natural pain signalling. Nobody received Semax for a pain-relief test in that serum experiment. The comparison page examines it alongside Selank.
Mental clarity accounts
Mental clarity, sustained focus and easier word recall recur in online accounts. Reports of little change, emotional flatness, tiredness, irritability, headache and nasal irritation also appear. Those are anecdotal accounts rather than clinical evidence; the word clarity gives a feeling a name without establishing its cause.
The word clarity has a particular pull on me. I doubt Semax recovery in injured rats predicts mental clarity during an ordinary working day. Long-term effects in healthy people and interactions with other brain-active medicines remain poorly characterised.
Semax has prescription registration in Russia and Ukraine, and no FDA or EMA approval. Research material lacks the checks required for medicines. Pregnancy, breastfeeding and repeated use with existing illnesses remain without established safety, and the experiments offer no validated self-treatment schedule.